TABLE 2.

Univariate and Multivariate Analysis of OS Using Cox Proportional Hazards Regression Model in Patients with Non-metastatic Disease (n=94)

Factor	HR (95% CI)	P-value
Univariate Analysis
Age (years)		0.02
Risk Group (low vs. intermediate)		0.01
Histology (favorable vs. unfavorable)		0.04
Site (favorable vs. unfavorable)		0.02
Chemotherapy (no vs. VADRC vs. VAC vs. other)		0.14
Protocol (yes vs. no)		0.03
KPS (>70% vs. ≤ 70%		0.16
Multivariate Analysis
COG Risk Group
Low (reference)	1.00
Intermediate	2.78 (1.40–5.53)	0.004
Protocol
Age ≤44, on protocol (reference)	1.00
Age ≤44, not on protocol	2.16 (1.04–4.49)	0.04
Age >45, not on protocol	3.03 (1.43–6.46)	0.004

Abbreviations: COG, Children’s Oncology Group; VAC, vincristine, dactinomycin, cyclophosphamide; VADRC, vincristine, doxorubicin, cyclophosphamide.